E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Post-operative pulmonary dysfunction induced by cardiopulmonary bypass in pediatric subjects undergoing surgery for congenital heart defects. |
|
E.1.1.1 | Medical condition in easily understood language |
Breathing difficulties following heart surgery that is caused by heart bypass in patients at or below the age of 18 undergoing surgery for inborn heart defects. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to determine if L-citrulline delivery given perioperatively reduces clinical sequelae of acute CPB-induced lung injury in pediatric subjects undergoing repair of congenital heart defects, as evidenced by the reduction of post-operative need for mechanical ventilation and inotrope therapy. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to evaluate the effect of L-citrulline compared with placebo regarding • safety and tolerability • hemodynamic improvement post-operatively • the usage and length of time on vasodilators • length of hospitalization • the duration of chest tube placement • the plasma concentrations of citrulline |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Subjects, parents, or legal guardian of the subject who are willing and able to sign informed consent • Male and female subjects aged ≤18 years of age • Infants, children and adolescents undergoing CPB for repair of a large unrestrictive VSD, an ostium primum ASD, or a partial or complete AVSD • Pre-operative echocardiogram that confirms the cardiovascular anatomy and defect to be surgically repaired • Patient weight must be 4.0 kg or greater at the time of screening |
|
E.4 | Principal exclusion criteria |
• Evidence of pulmonary artery or vein abnormalities on the pre-operative echocardiogram that will not be addressed surgically. Specific abnormalities excluded include the following: - Significant pulmonary artery narrowing not amenable to surgical correction - Previous pulmonary artery stent placement - Significant left sided AV valve regurgitation not amenable to surgical correction - Pulmonary venous return abnormalities not amenable to surgical correction - Pulmonary vein stenosis not amenable to surgical correction • Preoperative requirement for mechanical ventilation or i.v. inotrope support • Presence of fixed or idiopathic pulmonary hypertension (i.e. Eisenmenger’s Syndrome) prior to surgical repair • Pre-operative use of medications to treat pulmonary hypertension • Pregnancy; Sexually active females of child-bearing potential must be willing to practice an acceptable method of birth control for the duration of study participation (e.g. oral contraceptive, hormonal implant, intra-uterine device) • Participation in another clinical trial within 30 days of Screening or while participating in the current study, including the 28 days of follow-up post study drug administration. • Patient is < 28 days of age • Any condition which, in the opinion of the investigator, might interfere with the study objectives
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
A composite variable consisting of the longer of either (1) length of time on mechanical ventilation or (2) length of inotrope use. The definition of mechanical ventilation shall include invasive mechanical ventilation or noninvasive mechanical ventilation including bilevel (biphasic) positive airway pressure (BPAP) or continuous positive airway pressure (CPAP). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary Efficacy Endpoints • Length of time on mechanical ventilation • Length of time on positive pressure ventilation • Length of time of inotrope use • Inotrope score calculated each hour post-operatively from the time of separation from bypass until the completion of study drug; additionally, the total inotrope score over time until Day 28 or hospital discharge will be derived • Hemodynamic improvement (heart rate, systemic arterial blood pressure, oxygen saturation, and central venous pressure) • Thoracotomy output; duration and volume of chest tube drainage • Length of time of intubation • Length of PICU stay • Length of time on vasodilators • Length of hospitalization • Plasma concentrations of citrulline
Secondary Safety Endpoints • Occurrence of adverse and serious adverse events • Incidence of refractory hypotension • Change from baseline in laboratory values (serum electrolytes, blood urea nitrogen [BUN], creatinine, complete blood count [CBC] with differential, activated clotting time [ACT] & liver enzymes) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Germany |
Israel |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |